Alvotech Moves Ahead On Higher-Concentration Humira Rival
Executive Summary
Alvotech is moving ahead with developing its higher-concentration adalimumab biosimilar after completing enrollment in a European Phase III trial.
You may also be interested in...
People Round-Up: Alvotech Appoints Science Chief As Read Exits Pfizer
Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.
Alvotech And Prestige Strike Biosimilar Manufacturing Deal
Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.
Cipla And Alvotech Prime Emerging Markets Push With Adalimumab Deal
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.